A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design, Dose Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Ichorcumab (Primary) ; Apixaban
- Indications Thrombosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms TEXT-TKR
- Sponsors Janssen Research & Development
- 22 Nov 2017 Planned End Date changed from 24 Sep 2019 to 4 Oct 2019.
- 22 Nov 2017 Status changed from not yet recruiting to recruiting.
- 20 Oct 2017 Planned initiation date changed from 23 Oct 2017 to 25 Oct 2017.